Needham Maintains Buy on Cytokinetics, Lowers Price Target to $72
Needham Maintains Buy on Cytokinetics, Lowers Price Target to $72
Needham維持對細胞動力學的買入，將目標股價下調至72美元
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $108 to $72.
Needham分析師Serge Belanger 繼續對cytokinetics(NASDAQ:CYTK)股票給予買入評級，並將目標價格從108美元調低至72美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。